CVAC vs. TGTX, MRUS, XENE, BHVN, IDYA, FOLD, RYTM, ACAD, MLTX, and MORF
Should you be buying CureVac stock or one of its competitors? The main competitors of CureVac include TG Therapeutics (TGTX), Merus (MRUS), Xenon Pharmaceuticals (XENE), Biohaven (BHVN), IDEAYA Biosciences (IDYA), Amicus Therapeutics (FOLD), Rhythm Pharmaceuticals (RYTM), ACADIA Pharmaceuticals (ACAD), MoonLake Immunotherapeutics (MLTX), and Morphic (MORF). These companies are all part of the "pharmaceutical preparations" industry.
CureVac (NASDAQ:CVAC) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, community ranking, profitability and institutional ownership.
17.3% of CureVac shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 2.2% of CureVac shares are owned by insiders. Comparatively, 9.2% of TG Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
TG Therapeutics has higher revenue and earnings than CureVac. CureVac is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, TG Therapeutics had 1 more articles in the media than CureVac. MarketBeat recorded 5 mentions for TG Therapeutics and 4 mentions for CureVac. TG Therapeutics' average media sentiment score of 0.72 beat CureVac's score of 0.54 indicating that TG Therapeutics is being referred to more favorably in the news media.
CureVac has a beta of 2.64, indicating that its stock price is 164% more volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 2.23, indicating that its stock price is 123% more volatile than the S&P 500.
CureVac presently has a consensus price target of $10.00, indicating a potential upside of 168.82%. TG Therapeutics has a consensus price target of $29.83, indicating a potential upside of 45.07%. Given CureVac's higher probable upside, equities research analysts clearly believe CureVac is more favorable than TG Therapeutics.
TG Therapeutics received 628 more outperform votes than CureVac when rated by MarketBeat users. Likewise, 76.77% of users gave TG Therapeutics an outperform vote while only 52.27% of users gave CureVac an outperform vote.
TG Therapeutics has a net margin of 14.24% compared to CureVac's net margin of -463.49%. TG Therapeutics' return on equity of 31.34% beat CureVac's return on equity.
Summary
TG Therapeutics beats CureVac on 15 of the 18 factors compared between the two stocks.
Get CureVac News Delivered to You Automatically
Sign up to receive the latest news and ratings for CVAC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CVAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
